1Edelstein SL, Knowler WC, Bain RP, et at. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies[J]. Diabetes, 1997,46(4): 701-710.
2The DECODE study glcoup. European diabetes epidemiology group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American diabetes association diagnostic criteria[J]. Lancet, 1999,354(9179) : 617-621.
5Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance[J]. N Engl J Med, 2001,344 (18) :1390-1392.
6Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifeslyle intervention or metformin[J]. N Engl J Med,2002,346(23):1829-1830.
7Ronald Kahn C,Weir G C,King G L,et al.Joslin糖尿病学[M].潘长玉,译.北京:人民卫生出版社,2007:712.
2The DECODE study group. European diabetes epiderniology group. Diabetes epidemiology:collaborative analysis of diagnostic criteria in europe, Glucose tolerance and mortality: comparison of WHO and american dia betes association diagnostic criteria. Lancet, 1999,354: 617-621.
3Harris ML Impaired glucose tolerance in the U. S. population. Diabetes Care, 1989,12:464-474.
4Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment olin sulin resistance and type Ⅱ diabetes. Diabetes, 1996, 45: 1661-1669.
5Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med,2001, 344 : 1343-1350.
6Diabetes prevention program research group. Reduction in the in cidence of type 2 diabetes with lifestyle intervention or metformin. N EnglJ Med,2002, 346:393-403.
7Bennett SM, Agrawal A,Elasha H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med, 2004,21 :415-422.
2Kitaoto H. Efficacy of combination therapy of alpha-gluc- osidase inhibitor and insulin sensitizer in patients with type 2 diabetes[J]. Nippon Rinsho, 2002, 60 (Suppl 9) : 464.
3Chiasson JL, Josse RG, Leiter LA, et al. The effect ofac- arbose on insulin sensitivity in subjects with impaired glu- cose tolerance[J]. Diabetes Care, 1996,19(11) :1 190.
4Nijpels G, Boorsma W, Dekker JM, et aL A study of the effects of acarbose on glucose metabolism in patients pre- disposed to developing diabetes: the Dutch acarbose inter- vention study in persons with impaired glucose tolerance (DAISI) [J]. Diabetes Metab Res Rev, 2008,24 (8) : 611.
5Pan CY, Gao Y, Chen JW, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance[J]. Dia- betes Research and Clinical Practice, 2003, 61 (3) : 183.
6Laube H, Lima T, Heyen P. The effect of aearbose on in- sulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance[J]. Exp Clin Endocrinol Diabetes, 1998, 106(3) : 231.
7Chang AM, Smith M J, Bloem C J, et al. Effect of lower- ing postprandial hyperglycemia on insulin secretion in old- er people with impaired glucose tolerance[J]. American Journal of Physiology Endocrinology and Metabolism, 2004,287(5) :906.
8莫一丽.阿卡波糖对糖耐量异常的干预研究[J].医药前沿,2013(10):194.
9Pedersen TR, Olsson AG, Faergeman O, et al. Lipopro- tein changes and reduction in the incidence of major coro- nary heart disease events in the scandinavian simvastatin survival study(4S)[J]. Atheroscler Suppl, 2004,5 (3) : 99.
